EARLY CLINICAL ACTIVITY AND PHARMACODYNAMIC EFFECTS OF DUVELISIB, A PI3K-DELTA,GAMMA INHIBITOR, IN PATIENTS WITH TREATMENT-NA
Author(s): ,
Susan O'Brien
Affiliations:
MD Anderson Cancer Center,Houston,United States
,
Kerrie Faia
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
,
Kerry White
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
,
Mark Douglas
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
,
Kerstin allen
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
,
Jeffery Kutok
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
,
Jennifer Sweeney
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
,
Virginia Kelly
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
,
Ian Flinn
Affiliations:
Sarah Cannon Research Institute,Nashville,United States
,
John Byrd
Affiliations:
The Ohio State University Medical Center,Columbus,United States
Howard Stern
Affiliations:
Infinity Pharmaceuticals,Cambridge,United States
EHA Learning Center. O'Brien S. Jun 13, 2015; 103207
Dr. Susan O'Brien
Dr. Susan O'Brien

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: S434

Type: Oral Presentation

Presentation during EHA20: From 13.06.2015 12:15 to 13.06.2015 12:30

Location: Room A7

Background
Signaling via PI3K-δ and PI3K-γ has distinct and complementary effects on malignant B-cells and nonmalignant immune cells in chronic lymphocytic leukemia (CLL). Duvelisib, an oral dual inhibitor of PI3K-δ,γ, has shown clinical activity in a phase 1 study, IPI-145-02 (O’Brien, ASH 2014; Flinn, ASH 2014; Horwitz, ASH 2014).

Aims
The activity of duvelisib monotherapy in patients with treatment-naïve CLL from this study are reported here.

Methods
Following dose escalation, an expansion cohort of treatment-naïve CLL patients was enrolled (n=18). Response was based on iwCLL (2008) criteria. Safety included AEs and laboratory assessments. Pharmacodynamic assessments included peripheral blood (PB) flow cytometry for phospho-S473 AKT (pAKT) and Ki67, and measurement of serum chemokines and cytokines. Numbers of PB T-cell subsets were also monitored.

Results
As of Oct 2014, 18 treatment-naïve CLL pts received duvelisib 25 mg BID. The best ORR per iwCLL was 82% (PRs in 14/17 evaluable patients) with a median time on treatment of 53 weeks (range 8-69). Ten patients remain on treatment, while 8 discontinued, including 6 patients due to AEs. AEs overall were mostly Grade 1 or 2. The most common ≥ Grade 3 AEs were neutropenia (7/18) and ALT/AST increase (3/18). Inhibition of pAKT in CLL cells was rapid following a single dose and sustained through Cycle 2 Day 1 (C2D1). A reduction in the Ki67 proliferative fraction in both CLL and T-cells was also observed. Duvelisib resulted in reductions in the median serum levels of CCL3, CCL4, CCL17, CCL22, CXCL10, CXCL13, IL-10, IL-12p40, MMP-9, IL-16, and TNFα to ≤ 50% of baseline at C1D8 and/or C2D1 (p < 0.01).

Summary
Duvelisib 25 mg BID shows clinical activity in treatment-naïve CLL pts. The inhibition of pAKT and Ki67 in CLL cells suggests duvelisib inhibits the PI3K pathway and suppresses malignant cell proliferation in treatment-naive CLL patients. In addition, the effect of duvelisib on serum chemokines, cytokines, and T-cell proliferation suggests that modulation of the tumor microenvironment may contribute to the observed early clinical activity of duvelisib in patients with treatment-naïve CLL. These data support the further development of duvelisib in treatment-naïve CLL, including combinations with other targeted therapies.

Keyword(s): Chronic lymphocytic leukemia, Clinical data, Cytokine, PI3K

Session topic: CLL: Novel agents
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings